Ligand Pharmaceuticals Inc (LGND)
78.98
-0.96
(-1.20%)
USD |
NASDAQ |
Jun 25, 16:00
78.91
-0.07
(-0.09%)
After-Hours: 20:00
Ligand Pharmaceuticals Research and Development Expense (Annual): 24.54M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.54M |
| December 31, 2022 | 36.08M |
| December 31, 2021 | 32.10M |
| December 31, 2020 | 40.50M |
| December 31, 2019 | 55.91M |
| December 31, 2018 | 27.86M |
| December 31, 2017 | 26.89M |
| December 31, 2016 | 21.22M |
| December 31, 2015 | 11.00M |
| December 31, 2014 | 9.747M |
| December 31, 2013 | 9.274M |
| December 31, 2012 | 10.79M |
| December 31, 2011 | 10.29M |
| December 31, 2010 | 22.07M |
| December 31, 2009 | 39.87M |
| Date | Value |
|---|---|
| December 31, 2008 | 30.77M |
| December 31, 2007 | 44.62M |
| December 31, 2006 | 41.55M |
| December 31, 2005 | 30.71M |
| December 31, 2004 | 32.72M |
| December 31, 2003 | 66.68M |
| December 31, 2002 | 59.06M |
| December 31, 2001 | 51.10M |
| December 31, 2000 | 51.29M |
| December 31, 1999 | 59.44M |
| December 31, 1998 | 70.70M |
| December 31, 1997 | 72.40M |
| December 31, 1996 | 59.50M |
| December 31, 1995 | 41.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
24.54M
Minimum
2023
55.91M
Maximum
2019
37.83M
Average
36.08M
Median
2022
Research and Development Expense (Annual) Benchmarks
| ANI Pharmaceuticals Inc | 34.29M |
| Annovis Bio Inc | 38.79M |
| United Therapeutics Corp | 408.00M |
| ADMA Biologics Inc | 3.30M |
| Blueprint Medicines Corp | 427.72M |